The β-Lactamase Disk Test: A Modified Method to Detect Extended-Spectrum-β-Lactamases in Multidrug-Resistant *Escherichia coli* Isolates

Davood Kalantar-Neyestanaki,¹ Maryam Koshesh,² Zahra Hashemizadeh,¹ Shahla Mansouri,¹ Abbas Bahador,³ and Mohammad Savari³,*

¹Department of Microbiology and Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
²Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
³Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Received 2016 May 09; Revised 2016 October 04; Accepted 2016 October 05.

Abstract

**Background:** Most urinary tract infections (UTIs) are caused by *Escherichia coli* (*E. coli*) species. Due to infections outbreaks of *E. coli* strains with multiple mechanisms of resistance to β-lactam antibiotics, the sensitivity of confirmatory tests to detect the extended spectrum β-lactamases (ESBLs) have decreased.

**Objectives:** The current study aimed to introduce a modified method to detect ESBLs in Gram-negative bacilli.

**Methods:** Totally, 86 clinical isolates of *E. coli* resistant to extended-spectrum cephalosporins were collected from patients with UTIs in Kerman, Iran. The susceptibility of antibiotics was determined by disk diffusion method. ESBLs producing isolates were identified by combination double disk synergy test (CDDST) and β-lactamase disk test. The β-lactamase genes including *bla*TEM, *bla*SHV, *bla*CTX-M, *bla*OXA, and *bla*PER were detected by polymerase chain reaction (PCR) method and sequenced.

**Results:** All of the isolates were multidrug-resistant (MDR). In the current study 88% and 97.6% of the isolates were considered as ESBLs producing by CDDST and β-lactamase disk test, respectively. At least 92% of the isolates were positive for one of the *bla*CTX-M, *bla*OXA, *bla*PER, and *bla*SHV genes. The *bla*CTX-M, *bla*TEM, *bla*OXA-1 and *bla*SHV genes were detected in 74.4%, 61.6%, 14% and 2.3% of the isolates, respectively.

**Conclusions:** The β-lactamase disk test is appropriately sensitive to detect ESBLs in MDR isolates of *E. coli*.

**Keywords:** *Escherichia coli*, Multidrug-Resistant, β-lactamase

1. Background

UTIs are commonly caused by Gram-negative bacteria. *E. coli* is responsible for more than 80% of the UTIs (1). Broad-spectrum cephalosporins such as cefotaxime, ceftazidime and cefepime are among the most important antibiotics to treat infections caused by Gram-negative bacilli (2). Gram-negative bacilli such as *E. coli* become resistant to antibiotics through several mechanisms, including production of β-lactamase enzymes, changes in penicillin-binding proteins (PBPs), drug permeability reduction through mutations in porins and increase of the activity of efflux pumps (2, 3). Production of β-lactamase enzymes are among the most common mechanisms of resistance to β-lactam antibiotics in *E. coli* (2, 3). Several phenotypes of β-lactamase enzymes including extended spectrum β-lactamases (ESBLs), metallo-β-lactamases (MBLs) and Amp-C β-lactamases have reported in Gram-negative bacilli such as Enterobacteriaceae family, *Pseudomonas aeruginosa* (*P. aeruginosa*) and *Acinetobacter* spp. (3). There are several methods to identify ESBLs (3, 4). Combination double disk synergy test (CDDST) is a confirmatory method that can approve the detection of ESBLs in Gram-negative bacilli such as *Enterobacteriaceae* (4). Nowadays, due to outbreaks of isolates with multiple mechanisms of resistance to β-lactam antibiotics, sensitivity of CDDST method to detect ESBLs producing Gram-negative bacilli has decreased because of overlapping between the resistance mechanisms (5, 6). The simultaneous presence of multiple resistance mechanisms such as producing of ESBLs, AmpC, mutations in porins, lack of drug penetration into the bacterial cell and efflux pumps activity increase, may overlap with each other (7-9). Therefore, it is essential to introduce a method capable to detect ESBLs in Gram-negative bacilli with resistance to β-lactam antibiotics through multiple resistance mechanisms simultaneously. β-lactamase enzymes are secreted to periplasmic space of Gram-negative bacilli after synthesis (7-9).
lactamase disk test is a modified method to detect ESBLs in Gram-negative bacilli. In this method, after the destruction of the outer membrane by Tris-EDTA (TE) buffer, ESBLs are released into the medium culture and cause the hydrolysis of β-lactam antibiotics (9, 10). Outer membrane destruction leads to omission of other β-lactam resistance mechanisms such as activity of efflux pumps and lack of drug penetration (6).

2. Objectives

The current study aimed to evaluate the ability of the CDDST and β-lactamase disk test to detect ESBLs in clinical isolates of E. coli resistant to broad-spectrum cephalosporins and introduce a new modified method to detect ESBLs.

3. Methods

3.1. Bacterial Isolates

The current experimental study collected 86 MDRE. coli isolates from June 2014 to March 2015, from the urine sample of different patients demonstrating symptoms of UTIs admitted to hospitals of Kerman University of Medical Sciences. All isolates were considered as E. coli by standard biochemical tests including: oxidase test, lactose fermentation, growth on triple sugar iron medium, Simmons’ citrate agar and MRVP (methyl red-Voges Proskauer) broth.

3.2. Susceptibility Testing

Standard disk diffusion method on Mueller Hinton agar (CONDA Co; Spain) was used to determine antibiotic resistance profile according to Clinical and Laboratory Standards Institute (CLSI) recommendations (10). Antibiotic disks (HiMedia Co; India) included included: amoxicillin/clavulanic acid (10 µg/20 µg), cefotaxime (30 µg), ceftriaxone (30 µg), ceftazidime (30 µg), cefepime (30 µg), imipenem (10 µg), gentamicin (10 µg), ciprofloxacin (5 µg) and trimethoprim/sulfamethoxazole (1.25 µg/23.75 µg). E. coli strain ATCC 25922 was used as standard strain in disk diffusion method (11). The isolates resistant to at least three antibiotics from different classes were considered as MDR phenotypes according to the recommendations by Magiorakos et al. (12).

3.3. Identification of ESBLs Producing Isolates by CDDST

To perform this procedure, 0.5 McFarland standard was prepared from the clinical isolates and then cultivated on Mueller-Hinton agar (CONDA Co; Spain). On Mueller-Hinton agar the disks were placed as follows: ceftazidime (30 µg), cefotaxime (30 µg), cefpodoxime disks alone, and plus clavulanic acid (10 µg); they were placed at a distance of 20 mm from each other and then incubated overnight at 37°C. Isolates that their growth inhibition zone diameter around the clavulanic acid containing disks, were ≥ 5 mm of the non-clavulanic acid containing disks, considered as ESBLs producing isolates. In this method, Klebsiella pneumoniae (K. pneumoniae) ATCC700603 was used as positive control and E. coli ATCC 25922 as a negative control (4).

3.4. Identification of ESBLs-Producing Isolates by β-lactamase Disk Test

The design of this test was based on the presence of ESBLs in periplasmic space of Gram-negative bacilli (7-9). In this method, briefly, 100X TE buffer was diluted with normal saline in equal proportions (1/1). Then 20 mL of this solution was added to the blank disks (no antibiotic) and used after drying at room temperature. Then the cefotaxime sensitive P. aeruginosa ATCC 27853 (tested by 30 µg disk) was cultured on Mueller-Hinton agar. A cefotaxime disk (30 µg) was placed on the plate and two TE buffer-containing blank disks were placed on the top and bottom of it. Then colonies of the clinical isolates were added to each of the TE buffer containing disks. The TE buffer on the disk causes destruction in the outer membrane and leads to release β-lactamase enzymes into the culture medium. Flattening or indentation of the growth inhibition zone of the CTX disk at the side of blank disks containing the test isolates indicated that the release of ESBLs leads to cefotaxime sensitive P. aeruginosa growth toward cefotaxime disk in the plate (9, 10, 13). P. aeruginosa ATCC 27853 and E. coli ATCC 25922 were used as negative controls in this method (4).

3.5. Detection and Sequencing of β-lactamase Genes by PCR

To identify β-lactamase genes, bacterial DNA was extracted by boiling method. The genes blaTEM, blaSHV, blaOXA, blaPER1 and blaCTXM ESBL were identified, using specific primers listed in Table 1. The PCR was carried out in FlexCycler PCR Thermal Cycler (Analytik Jena, Germany) by Red PCR Master mix (Ampliqon Co, Denmark) according to the manufacture’s instruction, under the following conditions: initial denaturation in 95°C for five minutes followed by 30 cycles including: denaturation in 95°C for one minute, annealing for one minute (temperatures are listed in Table 1), extension in 72°C for one minute and the final extension in 72°C for five minutes. PCR reactions were performed in total volume of 25 µL. The master mix contained 12.5 µL of reaction mixture containing Taq DNA Polymerase, 0.5 µL of each forward and reverse primers (10 pM), 2 µL of target DNA (20 ng) and 9.5 µL of distilled water. The PCR products were electrophoresed on 1.2% agarose gel.
gel (Sigma, USA) containing Green viewer dye (Pars Tous, Iran), and then the gel was visualized by a Gel Doc TM XR image analysis station (Bio-Rad, Hercules, USA). PCR products were purified for sequencing after separation on an agarose gel using the GF-1 PCR Clean up Kit (VIVANTIS Inc., Malaysia) following the manufacturer’s instructions. Sequences were determined, assembled and compared with the sequences in the GenBank. K. pneumoniae ATCC700603 (positive for bla<sub>TEM</sub> and bla<sub>SHV</sub>) and P. aeruginosa strain KOAS (positive for bla<sub>PER</sub>) were used as control positive in PCR reaction.

3.6. Statistics Analysis

The sensitivity and specificity of phenotypic methods compared with those of PCR were analyzed by medCalc 8.1, available online (https://www.medcalc.org/calc/diagnostic_test.php).

4. Results

Among the 86 isolates, antibiotics resistance profile was as follows: cefotaxime (96.5%), ceftazidime (91.8%), cefepime (88.3%), amoxicillin/clavulanic acid (81.3%), ciprofloxacin (84.8%), trimethoprim/sulfamethoxazole (87.2%), gentamicin (32.5%) and nalidixic acid (93%). All isolates were sensitive to imipenem. All isolates were resistant to more than three antibiotics of different classes; therefore, they all were considered - as MDR phenotype. 88% and 97.6% of the isolates were considered as ESBLs producing by CDDST and β-lactamase disk tests, respectively (Figures 1 and 2). In CDDST, eight isolates were detected with no growth inhibition zones around cefotaxime, ceftazidime and cefpodoxime disks alone, and plus clavulanic acid and according to CLSI guidelines for CDDST were considered as negative for ESBLs production, however these eight isolates were positive for ESBLs genes (Table 2). All these eight isolates hydrolyzed cefotaxime in β-lactamase disk test and were considered ESBLs producing. Fifty-three (61.6%) isolates were positive for bla<sub>TEM</sub>, 64 (74.4%) for bla<sub>CTX-M</sub>, 12 (14%) for bla<sub>OXA</sub> and 2 (2.3%) for bla<sub>SHV</sub> genes. All isolates were negative for bla<sub>PER</sub> gene. Also 92% of the isolates (79 isolates) had at least one of the ESBLs genes including bla<sub>TEM</sub>, bla<sub>CTX-M</sub>, bla<sub>OXA</sub> and bla<sub>SHV</sub>. Co-existence rate of the ESBLs genes was as follows: 6 (7%) for bla<sub>OXA</sub>, bla<sub>CTX-M</sub> and bla<sub>TEM</sub>, 1 (1%) for bla<sub>SHV</sub>, bla<sub>CTX-M</sub> and bla<sub>TEM</sub>, 36 (41.8%) for bla<sub>TEM</sub> and bla<sub>CTX-M</sub>, 3 (3.5%) for bla<sub>TEM</sub> and bla<sub>OXA</sub>, 1 (1%) for bla<sub>SHV</sub> and bla<sub>CTX-M</sub> and 2 (2.3%) for bla<sub>OXA</sub> and bla<sub>CTX-M</sub>. PCR products were sequenced and then deposited into the GenBank under the following accession numbers: KU059762 (bla<sub>SHV</sub>), KU059763 (bla<sub>TEM</sub>), KX168501 (bla<sub>CTX-M</sub>) and KU059764 (bla<sub>OXA</sub>). Sensitivity, specificity, positive predictive value and negative predictive value of CDDST and β-lactamas disk test are shown in the Table 3.
Table 1. Primers Used in the Study

| Gene Target | Primer Sequences (5' - 3') | Annealing Temperature (°C) | Product Size (bp) | Reference |
|-------------|-----------------------------|-----------------------------|------------------|-----------|
| blaSHV      | F-TCAACGAAAAACACCTTG        | 56                          | 472              | (4)       |
|             | R-TCCCGCAGATAATACACC        |                             |                  |           |
| blaTEM      | F-CTTCGTTTTTGCTCACCC        | 56                          | 636              | (4)       |
|             | R-AACCAAAACACGCAAGCA        |                             |                  |           |
| blaPER      | F-ATGTTAATGCTTTAAGGC        | 49                          | 925              | (13)      |
|             | R-ANTTTGCTTGGCCGAA          |                             |                  |           |
| blaOXA      | F-TCAACTTTCAAGATGGCA        | 49                          | 601              | (14)      |
|             | R-GTGTTTAGGAATTGTGA         |                             |                  |           |
| blaCTX-M    | F-GCGTTTGGCATGGCAG          | 49                          | 550              | (35)      |
|             | R-ACCCGATATCGTTGCG         |                             |                  |           |

Table 2. Distribution of bla Genes Among Eight Isolates Negative by CDDST Method and Positive by β-Lactamase Disk Test method for ESBLs production

| Number of Isolates | CDDST | β-Lactamase Disk Test | blaTEM | blaTEM + blaCTX-M | blaTEM + blaOXA | blaTEM + blaOXA + blaCTX-M |
|--------------------|-------|-----------------------|--------|-------------------|-----------------|-----------------------------|
| 2                  | -     | 2                     | 2      | -                 | -               | -                           |
| 1                  | -     | 1                     | -      | -                 | 1               | -                           |
| 2                  | -     | 2                     | -      | -                 | -               | 2                           |
| 3                  | -     | 3                     | -      | 3                 | -               | -                           |

Abbreviation: CDDST, combination double disk synergy test.

5. Discussion

According to the definitions (12), all isolates examined in the current study were MDR, which indicated the association between ESBLs production and resistance to other antibiotics such as fluoroquinolones, aminoglycosides and trimethoprim/sulfamethoxazole (2, 3).

In the current study, 88% and 97.6% of the isolates were identified as ESBLs producing by the CDDST and β-lactamase disk test, respectively. According to the PCR results, 92% of isolates had at least one of the ESBLs genes such as blaTEM, blaCTX-M, blaOXA1 and blasSHV, these findings were close to β-lactamase disk test results. In this study and by the CDDST, eight of the isolates had no growth inhibition zone around cefotaxime, ceftazidime and cefpodoxime disk alone, and plus clavulanic acid and according to CLSI guidelines, due to the lack of inhibition zones around the disks containing clavulanic acid, were considered negative for ESBLs production (11). However all these eight isolates were considered ESBLs producing when β-lactamase disk test was used, due to hydrolysis of cefotaxime. This result may indicate the presence of multiple mechanisms of resistance to broad-spectrum cephalosporins in such isolates and when these mechanisms overlap, it leads to the reduction of CDDST sensitivity to identify the ESBLs producing isolates (3, 5). Several studies reported that CDDST was not suitable to detect ESBLs producing isolates. In previous studies in 2010 and 2012 in Kerman, Iran, E. coli and K. pneumoniae isolates with no growth inhibition zones around the cefotaxime,
ceftazidime and cefpodoxime disks alone, and plus clavulanic acid, were reported (16-19). Also in other reports in 2014 and 2015 in Tehran, conducted on 100 carbapenem-resistant P. aeruginosa isolates that were positive for blaTEM, \textit{bla} \textit{OXA}, and \textit{bla} \textit{SHV}, only three isolates were considered as ESBLs producing by CDDST method and 97 isolates exhibited no growth inhibition zones around the cephalaxine, ceftazidime and cefpodoxime disks, alone or in combination with clavulanic acid (5, 13). Also, Garrec et al., reported that in AmpC co-producers isolates CDDST method were not appropriate to detect ESBLs (sensitivity = 46% - 85%) (20-22). These results, similar to those of the current study, indicated that the presence of multiple mechanisms could decrease the sensitivity of ESBLs detection by CDDST method (20-22). The results of the current study and other studies indicated the emergence of Gram-negative bacilli strains that simultaneously had several mechanisms of resistance to \beta-lactam antibiotics; leading to the reduction of CDDST sensitivity to identify ESBLs producing Gram-negative bacilli (5, 9, 13).

In the current study, eight isolates positive for \beta-lactamase genes were negative for ESBLs production when tested by the CDDST, but they were considered as ESBLs producing by \beta-lactamase disk test. Since in the \beta-lactamase disk test, the outer membrane is disrupted, positive results in the test could indicate the role of outer membrane associated drug resistance mechanisms such as active drug efflux pumps and the lack of penetration due to mutations in porins (3, 7). In summary, it was demonstrated that \beta-lactamase disk test had high sensitivity (sensitivity = 96.34%) to detect ESBLs in Gram-negative bacilli, particularly in isolates with several mechanisms of resistance to \beta-lactam antibiotics. Finally, since the \beta-lactamase disk test is a modified method of ESBLs detection therefore more studies are needed to confirm its ability to detect ESBLs among Gram-negative bacilli.

5.1. Conclusion

The \beta-lactamase disk test could be a particularly appropriate method to detect ESBLs producing isolates with resistance to \beta-lactam antibiotics through several mechanisms.

Acknowledgments

The authors would like to thank the research council and student research committee of Kerman University of Medical Sciences for funding this research project (No. 198/94).

Footnote

Conflict of Interest: There was no conflict of interest regarding the materials and results of the current study.

References

1. Khoramrooz SS, Sharifi A, Yazdanpanah M, Malek Hosseini SA, Emaneini M, Gharibpour F, et al. High Frequency of Class I Integrons in Escherichia coli Isolated From Patients With Urinary Tract Infections in Yazd. Iran. \textit{Iran Red Crescent Med J.} 2016;18(1):26399. doi: 10.5882/ircmj.26399. [PubMed: 26584291].
2. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. \textit{Int J Med Microbiol.} 2010;300(6):379-9. doi: 10.1016/j.ijmm.2010.04.005. [PubMed: 20537585].
3. Willems E, Verhaegn J, Magerman K, Nys S, Cartuyvels R. Towards a phenotypic screening strategy for emerging beta-lactamases in Gram-negative bacilli. \textit{Int J Antimicrob Agents.} 2013;41(2):399-109. doi: 10.1016/j.ijantimicag.2012.07.006. [PubMed: 23280443].
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. M100-S25. 35. 2015.
5. Neyestanaki DK, Mirsalehian A, Rezagholizadeh F, Jabalameli F, Taherikalani, M, Emaneini M. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients. \textit{Burns}. 2014;40(8):1556-61. doi: 10.1016/j.burns.2014.02.010. [PubMed: 24767143].
6. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. \textit{J Hosp Infect.} 2009;73(4):345-54. doi: 10.1016/j.jhin.2009.02.021. [PubMed: 19596491].
7. Doy Y, Paterson DL. Detection of plasmid-mediated class C beta-lactamases. \textit{Int J Infect Dis.} 2007;11(1):191-7. doi: 10.1016/j.ijid.2006.07.008. [PubMed: 17339023].
8. Jacoby GA. AmpC beta-lactamases. \textit{Clin Microbiol Rev.} 2009;22(1):361-82. doi: 10.1128/CMR.00036-08. [PubMed: 1936439] Table of Contents.
9. Kalantar-Neyestanaki D, Emaneini M, Jabalameli F, Taherikalani M, Mirsalehian A. ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran. \textit{Iran J Microbiol.} 2015;7(5):247-50. [PubMed: 2679786].
10. Mirsalehian A, Kalantar-Neyestanaki D, Nourijelyani K, Asadollahi K, Taherikalani M, Emaneini M, et al. Detection of AmpC-beta-lactamases producing isolates among carbapenem resistant P. aeruginosa isolated from burn patient. \textit{Iran J Microbiol.} 2014;4(5):306-10. [PubMed: 24884591].
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. M100-S25. 2015;35(3):44-50.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. \textit{Clin Microbiol Infect.} 2012;18(8):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. [PubMed: 22793981].
13. Kalantar-Neyestanaki D, Jabalameli F, Mirsalehian A, Emaneini M. Evaluation of the \beta-lactamase disk test method in the detection of extended-spectrum-beta-lactamases in clinical isolates of multidrug-resistant pseudomonas aeruginosa. \textit{J Kerman Univ Med Sci.} 2016;21(3):11-11.
14. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum \beta-lactam beta-lactam antibiotics through several mechanisms.

Arch Clin Infect Dis. 2017;12(1):e39070.
15. Koshesh M, Mansouri S, Hashemizadeh Z, Kalantar Neyestanaki D. Identification of extended-spectrum β-lactamase genes and ampc-β-lactamase in clinical isolates of escherichia coli recovered from patients with urinary tract infections in Kerman, Iran. Arch Pediatr Infect Dis. 2016(Inpress).

16. Mansouri S, Abbasi S. Prevalence of multiple drug resistant clinical isolates of extended-spectrum beta-lactamase producing enterobacteriaceae in Southeast Iran. Iranian J Med Sci. 2015;35(2):101–8.

17. Mansouri S, Kalantar D, Asadollahi P, Taherikalani M, Emaneini M. Characterization of Klebsiella pneumoniae strains producing extended spectrum beta-lactamase and AMPC type beta-lactamases isolated from hospitalized patients in Kerman, Iran. Roum Arch Microbiol Immunol. 2012;71(2):81–6. [PubMed: 23210321].

18. Mansouri S, Kalantar Neyestanaki D, Shokoohi M, Halimi S, Beigverdi R, Rezagholezadeh F, et al. Characterization of AmpC, CTX-M and MBLs types of beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli producing Extended Spectrum beta-lactamases in Kerman, Iran. Jundishapur J Microbiol. 2014;7(2):8756. doi: 10.5812/jjm.8756. [PubMed: 25147671].

19. Kalantar D, Mansouri S. Emergence of multiple β-lactamases produced by Escherichia coli clinical isolates from hospitalized patient in Kerman, Iran. Jundishapur J Microbiol. 2010;2010(4, Autumn):37–45.

20. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae. J Clin Microbiol. 2011;49(3):1048–57. doi: 10.1128/JCM.02130-10. [PubMed: 21248086].

21. Jeong SH, Song W, Park MJ, Kim JS, Kim HS, Bae IK, et al. Boronic acid disk tests for identification of extended-spectrum beta-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC beta-lactamases. Int J Antimicrob Agents. 2008;31(5):467–71. doi: 10.1016/j.ijantimicag.2007.12.014. [PubMed: 18337065].

22. Song W, Bae IK, Lee YN, Lee CH, Lee SH, Jeong SH. Detection of extended-spectrum beta-lactamases by using boronic acid as an AmpC beta-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol. 2007;45(4):1180–4. doi: 10.1128/JCM.02122-06. [PubMed: 17301276].